Natural products as Zika antivirals

IF 10.9 1区医学 Q1 CHEMISTRY, MEDICINAL

Medicinal Research Reviews Pub Date : 2022-05-20 DOI:10.1002/med.21891

Yuhui Deborah Fong, Justin Jang Hann Chu

{"title":"Natural products as Zika antivirals","authors":"Yuhui Deborah Fong, Justin Jang Hann Chu","doi":"10.1002/med.21891","DOIUrl":null,"url":null,"abstract":"Zika virus (ZIKV) is an arbovirus belonging to the flavivirus genus and is transmitted in Aedes mosquito vectors. Since its discovery in humans in 1952 in Uganda, ZIKV has been responsible for many outbreaks in South America, Africa, and Asia. Patients infected with ZIKV are usually asymptomatic; mild symptoms include fever, joint and muscle pain, and fatigue. However, severe infections may have neurological implications, such as Guillain-Barré syndrome and fetal microcephaly. To date, there are no existing approved therapeutic drugs or vaccines against ZIKV infections; treatments mainly target the symptoms of infection. Preventive measures against mosquito breeding are the main strategy for limiting the spread of the virus. Antiviral drug research for the treatment of ZIKV infection has been rapidly developing, with many drug candidates emerging from drug repurposing studies, and compound screening. In particular, several studies have demonstrated the potential of natural products as antivirals for ZIKV infection. Hence, this paper will review recent advances in natural products in ZIKV antiviral drug discovery.","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":"42 5","pages":"1739-1780"},"PeriodicalIF":10.9000,"publicationDate":"2022-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med.21891","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicinal Research Reviews","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/med.21891","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 12

Abstract

Zika virus (ZIKV) is an arbovirus belonging to the flavivirus genus and is transmitted in Aedes mosquito vectors. Since its discovery in humans in 1952 in Uganda, ZIKV has been responsible for many outbreaks in South America, Africa, and Asia. Patients infected with ZIKV are usually asymptomatic; mild symptoms include fever, joint and muscle pain, and fatigue. However, severe infections may have neurological implications, such as Guillain-Barré syndrome and fetal microcephaly. To date, there are no existing approved therapeutic drugs or vaccines against ZIKV infections; treatments mainly target the symptoms of infection. Preventive measures against mosquito breeding are the main strategy for limiting the spread of the virus. Antiviral drug research for the treatment of ZIKV infection has been rapidly developing, with many drug candidates emerging from drug repurposing studies, and compound screening. In particular, several studies have demonstrated the potential of natural products as antivirals for ZIKV infection. Hence, this paper will review recent advances in natural products in ZIKV antiviral drug discovery.

查看原文本刊更多论文

作为寨卡病毒抗病毒药物的天然产物

寨卡病毒(ZIKV)是一种属于黄病毒属的虫媒病毒，通过伊蚊媒介传播。自1952年在乌干达发现人类感染寨卡病毒以来，寨卡病毒已在南美洲、非洲和亚洲造成多次疫情。感染寨卡病毒的患者通常无症状;轻微的症状包括发烧、关节和肌肉疼痛以及疲劳。然而，严重的感染可能会影响神经系统，如格林-巴罗综合征和胎儿小头畸形。迄今为止，尚无针对寨卡病毒感染的现有经批准的治疗药物或疫苗;治疗主要针对感染症状。预防蚊虫滋生的措施是限制病毒传播的主要策略。用于治疗寨卡病毒感染的抗病毒药物研究正在迅速发展，许多候选药物来自药物再利用研究和化合物筛选。特别是，一些研究已经证明了天然产物作为寨卡病毒感染抗病毒药物的潜力。因此，本文将对天然产物在寨卡病毒抗病毒药物发现方面的最新进展进行综述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medicinal Research Reviews 医学-药学

CiteScore

29.30

自引率

0.00%

发文量

审稿时长

2 months

期刊介绍： Medicinal Research Reviews is dedicated to publishing timely and critical reviews, as well as opinion-based articles, covering a broad spectrum of topics related to medicinal research. These contributions are authored by individuals who have made significant advancements in the field. Encompassing a wide range of subjects, suitable topics include, but are not limited to, the underlying pathophysiology of crucial diseases and disease vectors, therapeutic approaches for diverse medical conditions, properties of molecular targets for therapeutic agents, innovative methodologies facilitating therapy discovery, genomics and proteomics, structure-activity correlations of drug series, development of new imaging and diagnostic tools, drug metabolism, drug delivery, and comprehensive examinations of the chemical, pharmacological, pharmacokinetic, pharmacodynamic, and clinical characteristics of significant drugs.